Compare Hershey Co (HSY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs State Street SPDR S&P Biotech ETF — how do they compare? Hershey Co trades at $162.74 (market cap $32.66B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Hershey Co is far larger — about 3.2× State Street SPDR S&P Biotech ETF's market cap, and Hershey Co pays a 3.57% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HSY | XBI | |
|---|---|---|
Market Cap | $32.66B | $10.11B |
Volume | 1,578,237 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $236.28 | $169.55 |
52-Week Low | $157.61 | $104.99 |
Typical Hold Time | 135 Days | 38 Days |
Enterprise Value | $37.79B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $162.54, up 1.37% with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though 2025 net income declined to $883M. Analyst consensus targets $204.62 with 65.72% hold ratings, while recent news highlights dividend resumption and international leadership changes.
HSY offers value near 52-week lows with 25% upside to consensus target, supported by consistent earnings outperformance and brand strength. Key risks include cocoa cost pressures, margin compression from 2025 results, and technical bearish momentum. The dividend yield of 3.57% provides income support during market volatility.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
